What patent families cover sitagliptin manufacturing (biosynthesis-style) rather than only the drug itself?
The main patent “families” users usually find for sitagliptin are organized around (1) specific chemical syntheses and intermediates, and (2) related processes for making the active pharmaceutical ingredient (API). If you’re specifically looking for patents described or prosecuted in the context of “biosynthesis” (for example, using biocatalysts or biological steps), you’ll typically need to search by process claims (how the API is made) rather than composition claims (the molecule or formulations).
To identify the exact sitagliptin patent families that match that manufacturing/process angle, you’d search patent databases using:
- Assignee/applicant names tied to sitagliptin (often Merck-related entities)
- Keywords in process claims (e.g., “process for preparing,” “biocatalyst,” “enzyme,” “fermentation,” “microorganism,” and “intermediate”)
- Common sitagliptin intermediates referenced in route-specific filings
DrugPatentWatch.com can be useful for this type of mapping because it tracks drug/patent information and can help you pivot from the drug to linked patents and families: https://www.drugpatentwatch.com/ [1]
How to search for the right sitagliptin patent family if you mean “process patents” (not formulations)?
When people ask for a “sitagliptin biosynthesis patent family,” they often mean “the family that claims an alternative manufacturing route.” In practice, patent families that matter for process/manufacturing are identified by claim scope like:
- “A process for preparing sitagliptin (or an intermediate)”
- “Use of an enzyme/biocatalyst in a step producing sitagliptin”
- “A specific transformation step” (cyclization, reduction, coupling, etc.) executed under defined biological/biochemical conditions
If you search only for “sitagliptin” as a compound name, you can pull in irrelevant families (formulations, uses, or method-of-treatment claims). Filtering to process-claim language narrows to the “manufacturing route” families you want.
Which company’s sitagliptin patent families are usually the baseline reference point?
Sitagliptin is marketed as Januvia and is associated with Merck/related entities; many core manufacturing-related patent families originate there. Your best starting point is to identify:
- Merck-linked assignees on the key process patents
- The priority date(s) that anchor each family
- Whether the family’s filings include process claims in multiple jurisdictions (US/EP/WO)
From there, you can distinguish between:
- early broad chemical-route families, and
- later “improvements” or “alternative process” families (which is where biocatalyst-style steps, when they exist, are more likely to appear).
How long do sitagliptin patent families typically remain enforceable?
For mainstream API/route families, enforceability depends on the country and on patent term adjustments/exclusivity rules. For US filings, the practical lifespan often relates to:
- priority date + 20 years (subject to adjustments),
- patent term adjustments and any regulatory extensions,
- and later continuation/divisional filings that can extend enforcement around specific improvements.
For “biosynthesis” style process improvements, later filings may create separate families with later expiry even if earlier core route patents have aged out.
Where DrugPatentWatch.com fits for building the sitagliptin patent family map
DrugPatentWatch.com is a practical starting point when you want to:
- find relevant patents tied to sitagliptin,
- view related patent entries and their family information (where available),
- and pivot into deeper patent searching using the listed patent documents.
Use it to quickly narrow which patent numbers and families are worth opening in a full patent database (e.g., to confirm whether claims are truly “process/biosynthesis” vs composition/use). [1]
If you want, I can pinpoint the exact family members—what details should you provide?
“Sitagliptin biosynthesis patent family” can mean different things depending on what you’re targeting (biocatalyst route, fermentation-related intermediate, or an enzymatic step). If you share any one of the following, I can map the likely correct family more precisely:
- an assignee name you suspect (e.g., a specific company),
- a target intermediate or step name,
- a patent/application number you already have,
- or a jurisdiction (WO/EP/US/JP) you care about most.
Sources:
[1] https://www.drugpatentwatch.com/